A distinction between fit and nonfit patients is important to decide the most appropriate treatment for each patient. Some specific biological characteristics of the CLL cells, particularly loss ...

Ibrutinib remains a key treatment for relapsed chronic lymphocytic leukemia (CLL), but findings suggest that combining it ...

Quality-of-life (QOL) outcomes vary widely for patients receiving first-line treatment for chronic lymphocytic leukemia (CLL), according to research presented at the 2024 American Society of ...

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Chronic lymphocytic leukemia (CLL) is the most common type ... disease-related immunosuppression, and treatment-related immunosuppression. Taking precautions, like wearing a mask in public spaces ...

Edward Ratner has lived with chronic lymphocytic leukemia for a decade. Here, the Minneapolis doctor shares his rules for success.

Researchers sought to determine whether zanubrutinib is more beneficial than ibrutinib in patients with CLL/SLL.

Research into immunotherapy against cancer typically focuses on better recognition of cancer cells by the body's own immune system. Researchers at Amsterdam UMC and Moffitt Cancer Center have taken a ...

The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva®) for the treatment of ...

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...